Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The European Respiratory Journal|June 11, 2011
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3I Borget, J Cadranel, J-P Pignon, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2004
Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development GroupG Giaccone, E F Smit, M de Jonge, et al.
Endocrine-Related Cancer|June 24, 2024
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET studyE Baudin, J Capdevila, D Hörsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2010
Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumorsF Barlési, C Balleyguier, B Besse, et al.
ESMO Open|July 24, 2025
Efficacy of first-line treatments for advanced pulmonary sarcomatoid carcinomas: a real-world analysisK Amrane, B Cabarrou, G Justeau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 25, 2015
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortJ Mazières, F Barlesi, T Filleron, et al.
Respiratory Medicine and Research|May 17, 2020
Somatic profile in lung cancers is associated to reproductive factors in never-smokers women: Results from the IFCT-1002 BioCAST studyC Fontaine-Delaruelle, J Mazières, J Cadranel, et al.
ESMO Open|June 4, 2024
Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohortQ D Thomas, X Quantin, P Lemercier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 29, 2014
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studiesT Moran, J Wei, M Cobo, et al.
Pageof 3